サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1781986

希少疾患治療市場：治療領域別、薬剤タイプ別、投与形態別、流通チャネル別、患者年齢層別、国別、地域別-2025～2032年の世界産業分析、市場規模、市場シェア、予測

Rare Disease Treatment Market, By Therapeutic Area, By Drug Type, By Mode of Administration, By Distribution Channel, By Patient Age Group, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

出版日
ページ情報
英文 322 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.26円
希少疾患治療市場：治療領域別、薬剤タイプ別、投与形態別、流通チャネル別、患者年齢層別、国別、地域別-2025～2032年の世界産業分析、市場規模、市場シェア、予測
出版日: 2025年07月04日
発行: AnalystView Market Insights
ページ情報: 英文 322 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

希少疾患治療市場規模は2024年に2,162億5,049万米ドルとなり、2025～2032年にかけてCAGR 11.90%で拡大

希少疾患治療市場-市場力学

遺伝子研究の進歩が希少疾患治療開発を加速する

遺伝子研究の進歩は希少疾患治療に大きな影響を与え、標的治療や個別化医療を可能にしています。米国国立衛生ラボ（NIH）によると、希少疾患の80％近くが遺伝に起因しており、診断と治療におけるゲノミクスの重要性が強調されています。米国食品医薬品局（FDA）は、数多くの遺伝子治療に希少疾病用医薬品（オーファンドラッグ）のステータスを与え、迅速な承認と技術革新を促進しています。さらに、国際希少疾病研究コンソーシアム（IRDiRC）のような世界のイニシアチブは、診断法や治療法の開発を加速させることを目的としており、国やセグメントを超えた協力体制を促進しています。このような取り組みは、患者登録の増加や遺伝子スクリーニングプログラムと相まって、早期発見やオーダーメイドの治療を強化し、最終的には世界中の希少疾患の患者数百万人の生活の質を向上させています。

希少疾患治療市場-主要な洞察

弊社のリサーチアナリストの分析によると、世界市場は予測期間（2025～2032年）に約11.90%のCAGRで毎年成長すると推定されています。

治療領域別では、血液学が2024年に最大の市場シェアを示すと予測されました。

薬剤タイプ別では、生物製剤が2024年の主要薬剤タイプです。

投与形態別では、注射が2024年の主要投与形態でした。

流通チャネル別では、2024年の流通チャネルは専門薬局がリードしています。

患者年齢層別では、2024年には成人が主要患者年齢層となる

地域別では、北米が2024年の売上高でトップ

希少疾患治療市場-セグメンテーション分析

世界の希少疾患治療市場は、治療領域、薬剤タイプ、投与形態、流通チャネル、患者年齢層、地域に基づいてサブセグメンテーションされます。

市場は治療領域に基づいて9つのカテゴリーに分類されます：血液学、神経学、腫瘍学、代謝疾患、免疫学、感染症、内分泌疾患、心血管疾患、筋骨格系疾患です。血液内科は、標的療法を用いた血液疾患に重点を置いています。神経学は、先進治療を用いて希少な神経疾患に対処します。腫瘍学は、特殊ながん治療を開発します。代謝疾患は酵素補充に依存しています。免疫学は免疫不全を対象とし、感染症はまれな感染症を対象とします。内分泌疾患、心血管疾患、筋骨格系疾患には、新たな標的治療が登場しています。

市場は薬剤タイプによって2つのカテゴリーに分けられます：生物製剤と非生物製剤です。生物製剤は、抗体や遺伝子治療のような複雑な分子で希少疾病治療を支配し、標的作用を記載しています。非生物製剤には、より伝統的治療オプションを提供する低分子薬剤が含まれ、さまざまな希少疾患の症状管理や支持療法に用いられることが多いです。

希少疾患治療市場-地理的洞察

希少疾患治療市場は、ヘルスケアインフラ、規制施策、意識レベルの影響を受け、大きな地理的変動を示しています。北米は、先進的な医療制度、強力な政府支援、国立衛生ラボ（NIH）などの機関による希少疾患研究への充実した資金援助により、依然として有力な地域となっています。欧州は、包括的な希少疾患ネットワークや、より良い診断と治療のための各国間の連携を促進する欧州の・リファレンスネットワーク（ERNs）などのイニシアチブを有し、その後に続いています。アジア太平洋は、特に日本、中国、インドなどの国々で、希少疾患に対する政府の関心が高まり、ヘルスケアへのアクセスが拡大し、患者の意識が高まっていることを背景に、急速に台頭してきています。しかし、開発途上地域では診断施設が限られており、専門的な治療法も不足しているため、課題が残されています。希少疾患登録を改善し、国際的な研究パートナーシップを促進する世界の取り組みにより、地域間のアクセシビリティとイノベーションが引き続き強化され、世界中のアンメット・メディカル・ニーズに対応しています。

希少疾患治療市場-競合情勢

希少疾患治療市場の競合情勢には、大手製薬企業、バイオテクノロジー企業、希少疾患に特化した新興企業が混在しています。ジェンザイム（サノフィ傘下）、バイオマリン、バーテックスファーマシューティカルズなどの産業大手は、酵素補充療法や遺伝子療法などの革新的な治療法の開発によって強力なポートフォリオを確立しています。中小のバイオテクノロジー企業は、特定の希少疾患を対象としたニッチな治療を提供するようになってきており、開発と商業化のために大企業と提携することも多いです。学術機関、患者支援団体、製薬企業間の協力は一般的で、調査を推進し、医薬品承認を加速させています。希少疾病用医薬品の指定などの規制上の優遇措置が、希少疾病治療への市場参入と投資を後押ししています。遺伝子シークエンシング、個別化医療、生物製剤の絶え間ない進歩がイノベーションを促進し、希少疾患患者のアンメットニーズへの対応を目指す企業間の競争が世界的に激化しています。

目次

第1章 希少疾患治療市場概要

  • 調査範囲
  • 市場推定年数

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 希少疾患治療の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 希少疾患治療産業研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長展望マッピング
  • 規制枠組み分析

第5章 希少疾患治療市場：高まる地政学的緊張の影響

  • COVID-19パンデミックの影響
  • ロシア・ウクライナ戦争の影響
  • 中東紛争の影響

第6章 希少疾患治療市場情勢

  • 希少疾患治療市場シェア分析（2024年）
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 希少疾患治療市場-治療領域別

  • 概要
    • 治療領域別セグメントシェア分析
    • 血液学
    • 神経学
    • 腫瘍学
    • 代謝障害
    • 免疫学
    • 感染症
    • 内分泌疾患
    • 心血管疾患
    • 筋骨格系疾患

第8章 希少疾患治療市場-薬剤タイプ別

  • 概要
    • 薬剤タイプ別セグメントシェア分析
    • 生物製剤
    • 非生物製剤

第9章 希少疾患治療市場-投与形態別

  • 概要
    • 投与形態別セグメントシェア分析
    • 注射
    • 経口
    • 局所

第10章 希少疾患治療市場-流通チャネル別

  • 概要
    • 流通チャネル別セグメントシェア分析
    • 病院薬局
    • 専門薬局
    • 小売薬局

第11章 希少疾患治療市場-患者年齢層別

  • 概要
    • 患者年齢層別セグメントシェア分析
    • 小児
    • 成人
    • 高齢者

第12章 希少疾患治療市場-地域

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • オランダ
    • スウェーデン
    • ロシア
    • ポーランド
    • その他
  • アジア太平洋
    • 概要
    • アジア太平洋の主要メーカー
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • インドネシア
    • タイ
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第13章 主要ベンダー分析-希少疾患治療産業

  • 競合ダッシュボード
    • 競合ベンチマーキング
    • 競合ポジショニング
  • 企業プロファイル
    • Alexion Pharmaceuticals（AstraZeneca）
    • Amgen Inc.
    • Astellas Pharma Inc.
    • BioMarin Pharmaceutical Inc.
    • bluebird bio, Inc.
    • EveryONE Medicines
    • Grifols, SA
    • Horizon Therapeutics plc
    • Ionis Pharmaceuticals, Inc.
    • Novartis AG
    • Pfizer Inc.
    • PTC Therapeutics, Inc.
    • Regeneron Pharmaceuticals, Inc.
    • Roche Holding AG
    • Sanofi SA
    • Sarepta Therapeutics, Inc.
    • Swedish Orphan Biovitrum AB（Sobi）
    • Takeda Pharmaceutical Company Limited
    • Ultragenyx Pharmaceutical Inc.
    • Vertex Pharmaceuticals Incorporated
    • その他

第14章 アナリストの全方位展望

目次
Product Code: ANV5443

REPORT HIGHLIGHT

The Rare Disease Treatment Market size was valued at US$ 216,250.49 Million in 2024, expanding at a CAGR of 11.90% from 2025 to 2032.

The Rare Disease Treatment Market focuses on developing therapies for conditions affecting small patient populations, often with limited existing treatment options. Advances in genetic research and personalized medicine have expanded possibilities, with the World Health Organization noting that over 7,000 rare diseases impact approximately 400 million people worldwide. Increasing government incentives, such as orphan drug designations, encourage pharmaceutical innovation, while challenges include high research costs and complex regulatory pathways. Limited patient awareness and diagnostic delays often hinder early intervention, but growing collaborations between biotech firms, healthcare providers, and patient advocacy groups present opportunities to enhance treatment access and develop novel therapies. Emerging gene therapies and precision medicine approaches are opening new avenues, aiming to improve outcomes for patients with rare and often life-threatening conditions.

Rare Disease Treatment Market- Market Dynamics

Advancements in Genetic Research to Accelerate Rare Disease Treatment Development

Advancements in genetic research have significantly impacted rare disease treatment, enabling targeted therapies and personalized medicine. According to the National Institutes of Health (NIH), nearly 80% of rare diseases are genetic in origin, emphasizing the importance of genomics in diagnosis and treatment. The U.S. Food and Drug Administration (FDA) has granted orphan drug status to numerous gene therapies, facilitating faster approvals and encouraging innovation. Furthermore, global initiatives like the International Rare Diseases Research Consortium (IRDiRC) aim to accelerate the development of diagnostics and treatments, fostering collaboration across countries and disciplines. These efforts, combined with increased patient registries and genetic screening programs, are enhancing early detection and customized care, ultimately improving the quality of life for millions affected by rare diseases worldwide.

Rare Disease Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 11.90% over the forecast period (2025-2032)

Based on Therapeutic Area segmentation, Hematology was predicted to show maximum market share in the year 2024

Based on Drug Type segmentation, Biologics was the leading Drug Type in 2024

Based on Mode of Administration segmentation, Injectable was the leading Mode of Administration in 2024

Based on Distribution Channel segmentation, Specialty Pharmacies were the leading Distribution Channel in 2024

Based on Patient Age Group segmentation, Adult was the leading Patient Age Group in 2024

On the basis of region, North America was the leading revenue generator in 2024

Rare Disease Treatment Market- Segmentation Analysis:

The Global Rare Disease Treatment Market is segmented on the basis of Therapeutic Area, Drug Type, Mode of Administration, Distribution Channel, Patient Age Group, and Region.

The market is divided into nine categories based on Therapeutic Area: Hematology, Neurology, Oncology, Metabolic Disorders, Immunology, Infectious Diseases, Endocrine Disorders, Cardiovascular Conditions, and Musculoskeletal Conditions. Hematology focuses on blood disorders with targeted therapies. Neurology addresses rare neurological diseases using advanced treatments. Oncology develops specialized cancer therapies. Metabolic disorders rely on enzyme replacement. Immunology targets immune deficiencies, while infectious diseases involve rare infections. Endocrine, cardiovascular, and musculoskeletal conditions have emerging targeted therapies.

The market is divided into two categories based on Drug Type: Biologics and Non-biologics. Biologics dominate rare disease treatment with complex molecules like antibodies and gene therapies, offering targeted action. Non-biologics include small-molecule drugs that provide more traditional treatment options, often used for symptom management and supportive care in various rare conditions.

Rare Disease Treatment Market- Geographical Insights

The Rare Disease Treatment Market exhibits significant geographical variation influenced by healthcare infrastructure, regulatory policies, and awareness levels. North America remains a prominent region due to its advanced healthcare systems, strong government support, and robust funding for rare disease research, supported by agencies like the National Institutes of Health (NIH). Europe follows closely, with comprehensive rare disease networks and initiatives such as the European Reference Networks (ERNs) promoting collaboration among countries for better diagnosis and treatment. The Asia-Pacific region is rapidly emerging, driven by increasing government focus on rare diseases, expanding healthcare access, and growing patient awareness, especially in countries like Japan, China, and India. However, challenges remain in developing regions due to limited diagnostic facilities and a lack of specialized treatments. Global efforts to improve rare disease registries and foster international research partnerships continue to enhance accessibility and innovation across regions, addressing unmet medical needs worldwide.

Rare Disease Treatment Market- Competitive Landscape:

The competitive landscape of the Rare Disease Treatment Market features a blend of large pharmaceutical companies, biotechnology firms, and specialized rare disease-focused startups. Industry leaders like Genzyme (a Sanofi company), BioMarin, and Vertex Pharmaceuticals have established strong portfolios by developing innovative therapies such as enzyme replacement and gene therapies. Smaller biotechs are increasingly contributing niche treatments targeting specific rare conditions, often partnering with larger firms for development and commercialization. Collaborations between academic institutions, patient advocacy groups, and pharmaceutical companies are common, driving research and accelerating drug approvals. Regulatory incentives like orphan drug designations have encouraged market entry and investment in rare disease therapies. Continuous advancements in genetic sequencing, personalized medicine, and biologics are fostering innovation, intensifying competition among players aiming to address the unmet needs of rare disease patients globally.

Recent Developments:

In January 2025, Kerala is set to launch a rare disease patient registry and treatment clinic in Kozhikode this year. The initiative aims to improve early identification and specialized care for rare diseases, expanding access to advanced therapies and enhancing patient survival rates statewide.

In September 2024, India's government is launching a scheme to develop 12 indigenous drugs for eight rare diseases, including muscular dystrophy and Gaucher's disease. This initiative aims to drastically reduce treatment costs and improve access to life-saving therapies for rare disease patients nationwide.

In March 2025, the Mayo Clinic launched a landmark natural history study on autosomal dominant leukodystrophy, a rare neurodegenerative disorder. The initiative aims to improve diagnosis, track disease progression, and lay the groundwork for future genetic therapies and clinical trials in rare neurological diseases.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL RARE DISEASE TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Alexion Pharmaceuticals (AstraZeneca)
  • Amgen Inc.
  • Astellas Pharma Inc.
  • BioMarin Pharmaceutical Inc.
  • Bluebird bio, Inc.
  • EveryONE Medicines
  • Grifols, S.A.
  • Horizon Therapeutics plc
  • Ionis Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer Inc.
  • PTC Therapeutics, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Sarepta Therapeutics, Inc.
  • Swedish Orphan Biovitrum AB (Sobi)
  • Takeda Pharmaceutical Company Limited
  • Ultragenyx Pharmaceutical Inc.
  • Vertex Pharmaceuticals Incorporated
  • Others

GLOBAL RARE DISEASE TREATMENT MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032

  • Hematology
  • Neurology
  • Oncology
  • Metabolic Disorders
  • Immunology
  • Infectious Diseases
  • Endocrine Disorders
  • Cardiovascular Conditions
  • Musculoskeletal Conditions

GLOBAL RARE DISEASE TREATMENT MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • Biologics
  • Non-biologics

GLOBAL RARE DISEASE TREATMENT MARKET, BY MODE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Injectable
  • Oral
  • Topical

GLOBAL RARE DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Specialty Pharmacies
  • Retail Pharmacies

GLOBAL RARE DISEASE TREATMENT MARKET, BY PATIENT AGE GROUP- MARKET ANALYSIS, 2019 - 2032

  • Pediatric
  • Adult
  • Geriatric

GLOBAL RARE DISEASE TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Rare Disease Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Rare Disease Treatment Market Snippet by Therapeutic Area
    • 2.1.2. Rare Disease Treatment Market Snippet by Drug Type
    • 2.1.3. Rare Disease Treatment Market Snippet by Mode of Administration
    • 2.1.4. Rare Disease Treatment Market Snippet by Distribution Channel
    • 2.1.5. Rare Disease Treatment Market Snippet by Patient Age Group
    • 2.1.6. Rare Disease Treatment Market Snippet by Country
    • 2.1.7. Rare Disease Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Rare Disease Treatment Key Market Trends

  • 3.1. Rare Disease Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Rare Disease Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Rare Disease Treatment Market Opportunities
  • 3.4. Rare Disease Treatment Market Future Trends

4. Rare Disease Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Rare Disease Treatment Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Rare Disease Treatment Market Landscape

  • 6.1. Rare Disease Treatment Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Rare Disease Treatment Market - By Therapeutic Area

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Therapeutic Area, 2024 & 2032 (%)
    • 7.1.2. Hematology
    • 7.1.3. Neurology
    • 7.1.4. Oncology
    • 7.1.5. Metabolic Disorders
    • 7.1.6. Immunology
    • 7.1.7. Infectious Diseases
    • 7.1.8. Endocrine Disorders
    • 7.1.9. Cardiovascular Conditions
    • 7.1.10. Musculoskeletal Conditions

8. Rare Disease Treatment Market - By Drug Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug Type, 2024 & 2032 (%)
    • 8.1.2. Biologics
    • 8.1.3. Non-biologics

9. Rare Disease Treatment Market - By Mode of Administration

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Mode of Administration, 2024 & 2032 (%)
    • 9.1.2. Injectable
    • 9.1.3. Oral
    • 9.1.4. Topical

10. Rare Disease Treatment Market - By Distribution Channel

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
    • 10.1.2. Hospital Pharmacies
    • 10.1.3. Specialty Pharmacies
    • 10.1.4. Retail Pharmacies

11. Rare Disease Treatment Market - By Patient Age Group

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Patient Age Group, 2024 & 2032 (%)
    • 11.1.2. Pediatric
    • 11.1.3. Adult
    • 11.1.4. Geriatric

12. Rare Disease Treatment Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Rare Disease Treatment Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Rare Disease Treatment Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
    • 12.3.10. UK
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. UK Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.10.4. UK Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.10.5. UK Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
      • 12.3.10.6. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.10.7. UK Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
    • 12.3.11. France
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. France Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.11.4. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.11.5. France Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
      • 12.3.11.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.11.7. France Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
    • 12.3.12. Italy
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. Italy Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.12.4. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.12.5. Italy Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
      • 12.3.12.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.12.7. Italy Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
    • 12.3.13. Spain
      • 12.3.13.1. Overview
      • 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.3. Spain Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Spain Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Spain Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.13.7. Spain Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
    • 12.3.14. The Netherlands
      • 12.3.14.1. Overview
      • 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.3. The Netherlands Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.14.4. The Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.14.5. The Netherlands Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
      • 12.3.14.6. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.14.7. The Netherlands Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Overview
      • 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.15.7. Sweden Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
    • 12.3.16. Russia
      • 12.3.16.1. Overview
      • 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.3. Russia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Russia Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.16.7. Russia Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
    • 12.3.17. Poland
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Poland Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Poland Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Poland Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
    • 12.3.18. Rest of Europe
      • 12.3.18.1. Overview
      • 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.18.3. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.18.4. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.18.5. Rest of the Europe Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
      • 12.3.18.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.18.7. Rest of the Europe Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Rare Disease Treatment Key Manufacturers in Asia Pacific
    • 12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.4.5. APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.4.6. APAC Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
    • 12.4.7. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.8. APAC Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
    • 12.4.9. China
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. China Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.9.4. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.9.5. China Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
      • 12.4.9.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.4.9.7. China Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
    • 12.4.10. India
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. India Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.10.4. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.10.5. India Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
      • 12.4.10.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.4.10.7. India Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
    • 12.4.14. Indonesia
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Indonesia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Indonesia Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Indonesia Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
    • 12.4.15. Thailand
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Thailand Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Thailand Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Thailand Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
  • 12.5. Latin America (LATAM)
    • 12.5.1. Overview
    • 12.5.2. Rare Disease Treatment Key Manufacturers in Latin America
    • 12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.5.5. LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.5.6. LATAM Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
    • 12.5.7. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.8. LATAM Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Rare Disease Treatment Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By Patient Age Group, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Rare Disease Treatment Industry

  • 13.1. Competitive Dashboard
    • 13.1.1. Competitive Benchmarking
    • 13.1.2. Competitive Positioning
  • 13.2. Company Profiles
    • 13.2.1. Alexion Pharmaceuticals (AstraZeneca)
    • 13.2.2. Amgen Inc.
    • 13.2.3. Astellas Pharma Inc.
    • 13.2.4. BioMarin Pharmaceutical Inc.
    • 13.2.5. bluebird bio, Inc.
    • 13.2.6. EveryONE Medicines
    • 13.2.7. Grifols, S.A.
    • 13.2.8. Horizon Therapeutics plc
    • 13.2.9. Ionis Pharmaceuticals, Inc.
    • 13.2.10. Novartis AG
    • 13.2.11. Pfizer Inc.
    • 13.2.12. PTC Therapeutics, Inc.
    • 13.2.13. Regeneron Pharmaceuticals, Inc.
    • 13.2.14. Roche Holding AG
    • 13.2.15. Sanofi S.A.
    • 13.2.16. Sarepta Therapeutics, Inc.
    • 13.2.17. Swedish Orphan Biovitrum AB (Sobi)
    • 13.2.18. Takeda Pharmaceutical Company Limited
    • 13.2.19. Ultragenyx Pharmaceutical Inc.
    • 13.2.20. Vertex Pharmaceuticals Incorporated
    • 13.2.21. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us